We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-7.85%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.32B
AUM Growth
-$394M
Cap. Flow
-$88.3M
Cap. Flow %
-6.7%
Top 10 Hldgs %
63.8%
Holding
83
New
13
Increased
13
Reduced
16
Closed
22

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$114M
2
AZN icon
AstraZeneca
AZN
+$33.2M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$22.5M
4
ZTS icon
Zoetis
ZTS
+$21.1M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$17.9M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$42.2M
2
BPMC
Blueprint Medicines
BPMC
+$26.3M
3
ALGN icon
Align Technology
ALGN
+$25.1M
4
HRTX icon
Heron Therapeutics
HRTX
+$21.4M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$20.9M

Sector Composition

Rank Sector Weight
1 Healthcare 89.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
26
Protagonist Therapeutics
PTGX
$8.75B
$13M 0.98%
547,441
+65,184
+14% +$1.84M
SNDX icon
27
Syndax Pharmaceuticals
SNDX
$1.84B
$12.5M 0.95%
717,064
-234,162
-25% -$3.94M
CMPI
28
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$11.5M 0.87%
3,606,707
– –
INBX
29
DELISTED
Inhibrx, Inc. Common Stock
INBX
$11.5M 0.87%
514,640
+145,961
+40% +$3.73M
IMTX icon
30
Immatics
IMTX
$1.24B
$10.1M 0.77%
1,268,063
+241,440
+24% +$2.2M
JNCE
31
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$10.1M 0.76%
1,481,219
-101,558
-6% -$724K
CTIC
32
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$9.12M 0.69%
+1,952,691
New +$5.82M
ACET icon
33
Adicet Bio
ACET
$72.8M
$8.31M 0.63%
26,018
+6,581
+34% +$1.51M
INZY
34
DELISTED
Inozyme Pharma
INZY
$8.3M 0.63%
2,028,308
– –
BOLT icon
35
Bolt Biotherapeutics
BOLT
$7.36M
$7.55M 0.57%
137,722
– –
CCXI
36
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$7.52M 0.57%
+300,000
New +$8.43M
GRTX
37
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$7.34M 0.56%
3,083,712
– –
XNCR icon
38
Xencor
XNCR
$1.44B
$7.31M 0.55%
273,992
-263,038
-49% -$8.48M
AKUS
39
DELISTED
Akouos Inc
AKUS
$7.2M 0.55%
1,515,074
– –
BCYC
40
Bicycle Therapeutics
BCYC
$270M
$7.18M 0.54%
+163,559
New +$7.64M
OBSV
41
DELISTED
ObsEva SA Ordinary Shares
OBSV
$7.17M 0.54%
4,749,623
– –
SRPT icon
42
Sarepta Therapeutics
SRPT
$1.66B
$6.94M 0.53%
88,880
-31,852
-26% -$2.44M
IMGN
43
DELISTED
Immunogen Inc
IMGN
$6.8M 0.52%
1,428,169
-321,713
-18% -$1.78M
NCNA
44
NuCana
NCNA
$5.37M
$5.59M 0.42%
1,120
– –
FULC icon
45
Fulcrum Therapeutics
FULC
$248M
$5.43M 0.41%
229,509
-388,161
-63% -$5.49M
PTGX icon
46
CALL
Protagonist Therapeutics
PTGX
$8.75B
$4.74M 0.36%
200,000
-100,600
-33% -$2.83M
GERN icon
47
Geron
GERN
$911M
$2.59M 0.2%
+1,904,762
New +$2.12M
PFE icon
48
Pfizer
PFE
$140B
$2.56M 0.19%
+49,378
New +$2.56M
CYTK icon
49
Cytokinetics
CYTK
$11B
$2.32M 0.18%
62,944
-401,422
-86% -$14.3M
ICPT
50
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.63M 0.12%
100,000
-50,400
-34% -$789K
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2022 Portfolio in Review

As of Q1 2022, Sofinnova Investments held 83 positions worth $1.32B, down 23% from $1.71B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Sofinnova Investments withdrew a net $88.3M in Q1 2022, closing 22 positions and reducing 16 holdings. Its most notable exit was AbbVie, an estimated $42.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 85% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in CinCor Pharma, Inc. Common Stock worth $97.8M.

  • Sofinnova Investments's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 5,573,949 shares worth $97.8M.
  • Sofinnova Investments added most to United Therapeutics in Q1 2022, an estimated $13.2M increase.
  • Sofinnova Investments's biggest Q1 2022 reduction was Heron Therapeutics, cutting an estimated $21.4M.
  • Sofinnova Investments fully exited AbbVie in Q1 2022, selling an estimated $42.2M.
  • Sofinnova Investments's ten largest holdings make up 64% of its $1.32B portfolio in Q1 2022.
  • Sofinnova Investments opened 13 new positions and closed 22 in Q1 2022.
  • Sofinnova Investments's portfolio value fell 23% quarter-over-quarter to $1.32B.

Based on Sofinnova Investments's 13F filing for Q1 2022, filed 16 May 2022.